List view / Grid view
Since the development of the so-called soft ionisation techniques: electrospray ionisation and matrix-assisted laser desorption and ionisation in the 1980s and early 1990s and the development of high-resolution mass spectrometers, mass spectrometry (MS) has come to the fore in studying complex biological systems...
The history of molecular probes can be traced back to 1871 with the synthesis of fluorescein by Adolf von Baeyer1. Through the simple combination of phthalic anhydride and resorcinol in the presence of zinc chloride, the dawn of a completely new era in chemistry and biology began...
In the biomedical arena the imaging of biological samples has long been a mainstay technology, not only furthering our understanding of fundamental biology, but also playing a key role in designing strategies and therapies to combat infection and disease...
History has demonstrated that the use of companion in vitro diagnostic tests to select cancer patients positive for a drug target significantly improves response to targeted anti-cancer therapies...
21 September 2015 | By Drug Target Review
Included in this issue: Drug Development, Microfluidics, Proteomics, Ion Channels, GPCR, Imaging, Flow Cytometry, Enzymes
In this Proteomics In-Depth Focus: David J. Britton & Pedro R. Cutillas from Barts Cancer Institute ask should LC-MS/MS proteomics guide targeted drug selection for cancer patients? And Manfred Raida from the National University of Singapore explains how mass spectrometry and drug development come together...
In our Imaging In-Depth Focus: Dimitri Scholz and Jeremy C. Simpson from University College Dublin discuss trends in contemporary microscopy, Rudi Marquez and Zuzana Flachbartova share the bright future for molecular probes and Grischa Chandy from Molecular Devices LLC discusses changes and advantages with HCS microscopy...
All new drugs rely, to a greater or lesser extent, on pre-existing research and development. Much of this pre-existing research will have resulted in patented methods and products. A major challenge for all researchers is therefore to develop new drugs which do not infringe other company’s patents.
All biopharmaceutical products are associated with an intrinsic potential to induce immune responses in treated subjects. Regulatory agencies expect sponsors to evaluate and mitigate these risks during product development, applying a strategy that addresses product- and patient-related factors. Overall, understanding and controlling immunogenicity-related risks are attainable objectives, and approvability should…
Microfluidic miniaturisation, or the so-called ‘lab-on-a-chip’ concept, now encroaches on the fields of biology, medicine and pharmacology, and the nature of microfluidic technology (small volumes and high-throughput integration of fluid connections) means that it is outperforming conventional bench work. There has been an incredible need for microfluidic technology in the…
Ion channels modulate and control many fundamental physiological processes in various tissues and alterations in their functions give rise to a wide range of pathophysiologies, which makes them important drug targets. Indeed, for decades, drugs modulating ion channel activity have been targeted by the pharmaceutical industry. Historically, however, developing drugs…
The large family of pharmaceutical targets represented by G-protein coupled receptors (GPCRs) are usually involved in a number of intracellular effector pathways, leading to many cellular outcomes. In recent years it has been uncovered that different ligands of a given GPCR may engage the pathways selectively, in that ligands that…
Undoubtedly, you will have noticed the increase in the number of publications utilising flow cytometry, heard it mentioned more in meetings and probably even been targeted by several companies trying to sell you their latest cytometer. The rapidly advancing technology behind the cytometer and an increase in applications that use…
21 September 2015 | By SomaLogic
The SOMAscan™ assay is a highly multiplexed, sensitive, quantitative and reproducible proteomic tool for discovering biomarkers for drug discovery...
21 September 2015 | By BioTek
The Synergy Neo2 Multi-Mode Reader is designed to provide high temporal resolution in drug target kinetics applications...
